ArticleThe New England journal of medicine2016
Acute Myeloid Leukemia - Many Diseases, Many Treatments.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.Blood · 2021Trial
- Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Hexamethylene amiloride synergizes with venetoclax to induce lysosome-dependent cell death in acute myeloid leukemia.iScience · 2024Article
- Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.Journal of managed care & specialty pharmacy · 2022Article
- High Expression of DC-STAMP Gene Predicts Adverse Outcomes in AML.Frontiers in genetics · 2022Article
- High expression of B4GALT1 is associated with poor prognosis in acute myeloid leukemia.Frontiers in genetics · 2022Article
- Role and Mechanism of lncRNA-pvt1 in the Pathogenesis of Acute Lymphoblastic Leukemia in Children.Computational and mathematical methods in medicine · 2022Article
- Topoisomerase Assays.Current protocols · 2021Article
- Article
- Identification ofJournal of oncology · 2021Article
- Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML.Cancer medicine · 2020Article
- Identification and Validation ofOncoTargets and therapy · 2020Article
- Intensive patient's care program reduces anxiety and depression as well as improves overall survival inTranslational cancer research · 2019Article
- Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.Blood advances · 2018Article
- Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations.OncoTargets and therapy · 2018Article
- Cytogenetic profile of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan.Pakistan journal of medical sciencesArticle
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27959719What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.